The zinc finger transcription factor Gfi1 (growth factor-independent-1) has been involved in various cellular differentiation processes. Gfi1 acts as a transcriptional repressor and splicing control factor upon binding to cognate binding sites in regulatory elements of its target genes. In this study, we report that Gfi1-deficient mice develop autoimmunity. Gfi1-deficient peripheral B cells show a hyperproliferative phenotype leading to expansion of plasma cells, increased levels of nuclear autoantibodies, and Ig deposition in brain and kidneys. Dysregulation of multiple transcription factors and cell cycle control elements may contribute to B cell-dependent autoimmunity. Gfi1 thus emerges as a novel master regulator restricting autoimmunity. The Journal of Immunology, 2008, 181: 6222-6229.
T he immune system needs to maintain a fine-tuned balance of activation and tolerance to protect the host from microbial challenge and to avoid autoimmunity. This equilibrium is controlled at multiple checkpoints (1) . Not surprisingly, most autoimmune diseases represent complex traits. Only a few monogenic traits have been identified in humans and mice that predispose to autoimmunity (2) .
Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, primary Sjogren's syndrome, or systemic sclerosis, are usually associated with humoral and cellular abnormalities. Although previously the pathogenic role of T cells has been emphasized, recent discoveries have unraveled the importance of B cells in controlling autoimmunity, particularly in systemic lupus erythematosus (3) . B cells mediate autoimmunity by secretion of pathogenic autoantibodies, presentation of autoantigens to T cells, and production of proinflammatory cytokines (4, 5) . Mechanisms of self-tolerance by B cells involve deletion of autoimmune B cells, receptor editing, and allelic exclusion of autoreactive BCRs, as well as anergy and clonal ignorance of autoreactive B cells (1, 5) .
Importantly, mouse studies have highlighted to role of modifier genes in the pathophysiology of autoimmunity. For example, in the BCR-transgenic mouse models established to study autoreactive B cells, spontaneous activation of autoreactive B cells and autoantibody secretion are only found when the Ig transgenes are crossed to an "autoimmune background", but not in mice with "nonautoimmune background" (6 -8) .
The analysis of lupus-prone murine models has contributed significantly to unraveling the immunological processes that mediate autoimmunity (9) . Currently, three lupus-prone mouse strains serve as the predominant models of human systemic lupus erythematosus. The classic lupus-prone strains include the New Zealand Black and New Zealand White strains, the BXSB strain, and the MRL and MRL/lpr strains, respectively. These strains develop the characteristic features of lupus, including increased circulating autoantibodies and IgG, immune complex deposition, and kidney disease (9) . The immunological mechanisms that mediate disease manifestation in these strains are quite different as demonstrated by their differing responses to immunological challenge and T or B cell depletion. In addition to spontaneous autoimmune models, studies in various murine knockout models have highlighted the critical importance of tightly regulated BCR signals in controlling B cell proliferation and B cell-mediated autoimmunity (10 -14) .
Plasma cells are terminally differentiated, Ab-secreting, B lineage cells that develop from naive marginal zone and follicular B cells after Ag encounter (15) . Plasma cells are critical for an effective immune response but may cause severe pathology by secreting autoantibodies mediating autoimmunity as soluble Abs or as immune complexes (e.g., myasthenia gravis, Grave's disease, lupus erythematosus, and rheumatoid arthritis (15, 16) . Thus, activation of mature B cells, secretion of Ab, and survival of plasma cells need to be tightly controlled (15, 16) .
Transcription factors play a pivotal role in the development, differentiation, and functions of the immune system. Three transcription factors, namely Blimp1, XBP1, and IRF4, have been reported to play a crucial role in the development of plasma cells (15, 16) . Not surprisingly, mounting evidence documents the importance of transcription factors in the control of autoimmunity. To date, a number of transcription factors such as NF-B, STAT, AP-1, T-bet, NFAT, Forkhead, IFN regulatory factor, and Ets have been implicated in the pathogenesis of autoimmunity (17) . However, the relative importance of each of these transcription factors in the manifestation of specific autoimmune diseases remains largely unknown.
Gfi1 (growth factor-independent-1) is a zinc finger molecule of the SNAG family acting as a transcriptional repressor in multiple cell lineages. Originally identified as a retroviral insertion site in a thymoma cell line (18) , recent evidence links Gfi1 to the control of differentiation in myeloid cells (19 -21) , hematopoietic stem cells (22, 23) , T cells (24, 25) , B cells (26) , endocrine cells (27) , and neuronal cells (28, 29) . Gfi1 binds to cognate sites in regulatory elements of a variety of target genes (30) and mediates transcriptional repression in part by recruitment of histone-modifying enzymes (31) . Furthermore, Gfi1 has been shown to control splicing events (32) .
In this study, we analyze the role of Gfi1 in mediating an autoimmune phenotype in Gfi1-deficient mice and provide evidence that Gfi1 acts as a control factor restricting B cell-mediated autoimmunity.
Materials and Methods

Mice
All mice were bred and maintained under specific pathogen-free conditions in the central animal facility at Hannover Medical School (Hannover, Germany). Gfi1
Ϫ/Ϫ mice and Gfi1 GFP/ϩ mice were kindly provided by T. Möröy (University of Essen, Essen, Germany). Gfi1
Ϫ/Ϫ mice were generated by replacing exons 2, 3, 4, and 5 of Gfi1 by neomycin resistance gene, which results in the absence of Gfi1 protein in all organs (19) . Gfi1 GFP/ϩ knockin mice were generated by replacing exons 3, 4, and 5 of Gfi1 with GFP cDNA. The levels of Gfi1 protein expression in Gfi1 ϩ/ϩ and Gfi GFP/ϩ mice are comparable. Gfi1 Ϫ/Ϫ and Gfi GFP/ϩ mice were backcrossed with C57BL/6 for seven generations. NOD/SCID mice were obtained from Charles River Laboratories and were maintained in the pure NOD background. In all experiments, age-and sex-matched mice were used. All animal experiments were approved by the institutional review board of Hannover Medical School.
Flow cytometry
Single cell suspensions were analyzed by flow cytometry using FACScan or FACSCanto and CellQuest software, FACSDiva software (BD Biosciences), or Flow Jo software (Tree Star), respectively. Cell sorting of defined subpopulations was performed using a MoFlo cell sorter (DakoCytomation) or a FACSAria cell sorter (BD Biosciences), respectively.
The following mAbs (all from BD Pharmingen) were used: B220, IgM, CD19, and CD138. In all experiments, cells were also stained with corresponding isotype-matched mAbs. Cells reacted with biotinylated mAbs were incubated with fluorochrome-conjugated streptavidin-PerCP or streptavidin-allophycocyanin (BD Pharmingen). All fluorescence intensity plots are shown in log scales.
ELISA
Serum Ig levels were determined by enzyme-linked immunosorbent assay (ELISA), using Abs specific for each isotype (IgA, IgG2a, IgG2b, and IgM; BD Pharmingen). Anti-nuclear Abs were quantified using a commercially available ELISA kit (Alpha Diagnostics).
Western blotting
For Western blot analysis, 20 g of protein was loaded on an 8 or 10% SDS gel, separated by electrophoresis, and blotted onto nylon membranes. The membranes were exposed to reacting with Erk1/2p, Erk1/2 (Cell Signaling Technologies), Lyn, p-Lyn Ccna2, Ccnb2, p21, and GAPDH (Santa Cruz Biotechnologies) followed by staining with secondary Abs conjugated to HRP. The enzymatic reaction was visualized using ECL reagents (ECL kit; Amersham Biosciences).
B cell proliferation assays and calcium flux
CD19
ϩ cells were isolated from spleen using magnetic microbeads (Miltenyi Biotec). Purified B cells (2 ϫ 10 5 ) were cultured in 96-well plates containing complete RPMI 1640 supplemented with the stimuli recombinant murine IL-4 (Peprotech), anti-CD40 (BD-Pharmingen), anti-IgM (Southern Biotechnologies), or LPS (Sigma-Aldrich), each at a final concentration of 10 ng/ml for 2 days. On day 3 of culture, the cells were pulsed with 
In vivo B cell transfer
For B cell transfer experiments, 1 ϫ 10 6 CD19 ϩ B220 ϩ CD138
Ϫ
CD43
Ϫ splenic B cells obtained from 4-wk-old mice were injected i.v. into congenic NOD/SCID mice. Eight weeks after injection the mice were bled and anti-nuclear serum autoantibodies were measured by ELISA (Alpha Diagnostics). Twelve weeks after injection, mice were sacrificed and pathological studies were performed.
In vivo BrdU studies
In vivo incorporation of BrdU into CD19 ϩ CD138 ϩ cells was assessed using an allophycocyanin BrdU flow kit (BD Pharmingen). After a single i.p. injection of BrdU (1 mg per 6 g of mouse weight; Sigma-Aldrich), an admixture of 1 mg ml Ϫ1 BrdU was added to the drinking water for 5 days. Mice were sacrificed and bone marrow cells were prepared, stained with Abs recognizing CD19, B220, CD138 and BrdU, and analyzed by flow cytometry.
RNA extraction and real-time PCR
Total RNA was isolated using commercially available kit systems (Absolutely RNA Miniprep kit; Stratagene). cDNA was synthesized using an oligo(dT) primer and Expand reverse transcriptase (Roche). The PCR was performed in duplicates using the 7500 real-time PCR system and power SYBR Green PCR master mix (Applied Biosystems) according to the manufacturer's instructions. Primer pairs used in the study are indicated in supplemental table 2. 4 
Histopathology and immunofluorescence
Animals were perfused with 4% paraformaldehyde. Tissues were embedded in paraffin. Immunocytochemistry was performed with a biotin-avidin 4 The online version of this article contains supplemental material.
FIGURE 1. Prevalence of clinical symptoms in Gfi1
Ϫ/Ϫ mice and wildtype mice transplanted with Gfi1 Ϫ/Ϫ bone marrow. Upper panel, A cohort of 30 mice was followed clinically and their clinical status was monitored for ataxia, colitis, hunching, eczema, and hyperactivity. Mice were scored either positive or negative, and the fraction of positive mice was plotted. Data are pooled from five studies consisting of six mice each. Lower panel, A cohort of 30 congenic wild-type mice was transplanted with bone marrow from Gfi1 Ϫ/Ϫ mice and followed clinically for the occurrence of clinical symptoms. Data are pooled from three studies consisting of 10 mice each. technique using primary Abs against the following targets: CD3 (Serotex), B220 and Mac3 (BD Pharmingen), CD138 (BD Pharmingen), Ig (Amersham Biosciences), glial fibrillary acidic protein (NeoMarkers), and complement C9 (a gift of Dr. P. Morgan, Cardiff, University, Cardiff, U.K.).
To detect reactivity of autoantibodies to brain tissue, wild-type brain cryosections were blocked and exposed to blood serum obtained from Gfi1 ϩ/ϩ or Gfi1 Ϫ/Ϫ mice, respectively. After a series of washing steps, the sections were incubated with FITC-conjugated goat-anti-mouse Ig (DakoCytomation) Abs. To detect Ig deposits in kidneys, renal cryosections were incubated with FITC-conjugated goat-anti-mouse Ig (DakoCytomation) Abs. Imaging analysis was done using a Zeiss Axiovert 200 microscope. Electron microscopy was performed following standard Epon embedding and ultrathin sectioning.
Microarray analysis and bioinformatics
Gene expression levels were determined by means of the Affymetrix microarray suite 5.0 (MAS 5.0). MAS 5.0 software algorithms allow quantitative estimation of gene expression and p values to establish a confidence level concerning the accuracy of measurement of an mRNA of interest (detection p value) and changes in gene expression (change p value). Concerning the measured p values, the criteria of present (P) or absent (A) define the quality of signal measurement, and increase (I) or decrease (D) define the signal change, respectively. For normalization, all array experiments were scaled to a target intensity of 150, otherwise using the default values of the microarray suite. Filtering of the results was done as follows. Genes are considered as regulated when their fold change is Ն1.5 or ՅϪ1.5, the change p value is not "NC" (no change), and at least one of the two compared signals was detected with high accuracy (absent call for both signals were not allowed). Differentially expressed transcription factors were manually determined based on the information available at the Gene Ontology database (www.geneontology.org/).
Statistical analysis
Data are presented as mean Ϯ SEM. Statistical significance was assessed using a two-sided Student's test. Values of p Ͼ 0.05 were considered to be non significant (NS) and values of p Ͻ 0.05 and p Ͼ 0.01 were represented as ‫.ء‬ p Ͻ 0.01 and p Ͼ 0.001 were represented as ‫ءء‬ and p Ͻ 0.001 were represented as ‫.ءءء‬
Results
While studying the developmental biology of dendritic cells in Gfi1-deficient mice (21), we noted that wild-type mice transplanted with Gfi1-deficient bone marrow developed ataxia and behavioral abnormalities, in particular a phenotype of "rotatory dancing" (supplemental videos 1 and 2). Furthermore, both Gfi1-deficient mice and wild-type mice transplanted with Gfi1-deficient bone marrow developed progressive neurological symptoms, eczema, and colitis ( Fig. 1) , suggesting that this phenotype depends on a dysfunctional hematopoietic system. As previously documented (19, 20) , Gfi1-deficient mice had a reduced lifespan when compared with wildtype mice and died at the age of 3-6 mo (supplemental figure 1) . Previously, movement disorders seen in aging Gfi1-deficient mice had been attributed to inner ear (29) and cerebellar dysfunction (28) . We hypothesized that the neurological symptoms might at least partially represent manifestations of an autoimmune pathophysiology and therefore sought to systematically study potential factors contributing to autoimmunity.
Autoimmunity in Gfi1-deficient mice
First, we analyzed paraffin-embedded brain sections from Gfi1 Ϫ/Ϫ and Gfi1 ϩ/ϩ mice in greater detail. In line with previous reports (29), we were unable to document any gross structural abnormalities in the brains of Gfi1 Ϫ/Ϫ mice. However, we detected occasional meningeal inflammatory infiltrates (characterized by the presence of B cells, C9 deposition, and glial fibrillary acidic protein expression) and a striking deposition of Ig in Gfi1 Ϫ/Ϫ brains ( Fig. 2A) . We also measured serum levels of anti-nuclear autoantibodies in 8-and 16-wk-old Gfi1 Ϫ/Ϫ and Gfi1 ϩ/ϩ mice, respectively. Gfi1
Ϫ/Ϫ mice showed anti-nuclear Abs that increased with age (Fig. 2B) . Interestingly, serum of Gfi1 Ϫ/Ϫ mice gave rise to a nuclear staining pattern in native brain cryosections, whereas no autoantibodies could be detected in serum of wild-type control mice (Fig. 2C) . A pathophysiological role of anti-nuclear autoantibodies was further illustrated by analysis of kidneys revealing subendothelial electron-dense deposits in the glomerular basement membrane (Fig. 2, D and E) . These data suggest that Gfi1-deficient mice suffer from autoantibody-mediated immunopathology.
Analysis of the peripheral B cell compartment in Gfi1-deficient mice
Because the onset of Ab-mediated autoimmunity has been linked to increased B cell proliferation and plasmacytosis in various transgenic mouse models (33), we characterized the peripheral B cell compartment in greater detail. Early investigations in Gfi1-deficient mice revealed a paucity of mature B cells in bone marrow (19, 20, 24, 26) . In contrast, peripheral lymph nodes and spleens appeared enlarged in size when compared with those of control mice (Fig. 3A) . Overall, CD19
ϩ B cells of Gfi1-deficient mice exhibited an activated phenotype as documented by surface expression of CD43 (supplemental figure 2A) . Further, increased surface expression of MHC class II and costimulatory molecules 
B220
Ϫ cells was seen, a subpopulation representing plasma blasts and terminally differentiated plasma cells as shown by expression of CD138 (Fig. 3B) . Increased numbers of CD138 ϩ cells were also seen in peripheral and mesenteric lymph nodes (Fig. 3C) . Despite this marked increase in plasma cells in peripheral lymph nodes, the lymph node architecture remained preserved (Fig. 3D) . Furthermore, no destructive plasma cell infiltrates were seen in bones or other organs, suggesting that the plasma cell expansion represented benign hyperplasia. In view of our observation of increased plasma blasts/cells in Gfi1 Ϫ/Ϫ mice, we were interested to know whether Gfi1 is selectively expressed in this B cell subpopulation. We made use of a transgenic GFP reporter strain (34) that allows determination of the transcriptional activity of the Gfi1 locus by FACS analysis. As shown in Fig. 3E , GFP expression was markedly enhanced in CD138 ϩ B cells when compared with CD138 Ϫ B cells, suggesting that Gfi1 may indeed play a regulatory role in Ab-secreting cells. This increased expression level of the surrogate marker GFP in the GFP reporter cells was paralleled by increased transcriptional activity of the Gfi1 locus in CD138 ϩ B cells when compared with CD138 Ϫ B cells by RT-PCR (supplemental figure 3) , suggesting that this effect was not secondary to GFP accumulation in CD138 ϩ B cells. To assess whether plasmacytosis in Gfi1-deficient mice might lead to hypergammaglobulinemia, serum Ig levels were quantified by ELISA. As shown in Fig. 3F, Gfi1 Ϫ/Ϫ mice showed a selective increase in IgA, IgG2a, and IgE isotypes but normal levels of IgG1, IgG2b, IgG3, and IgM levels.
Functional characterization of peripheral B cells
Next, we asked the question of whether the observed plasmacytosis might ensue from unrestricted proliferation of B-lineage cells. Purified CD19 ϩ cells were stimulated in vitro and their proliferation was measured by [ 3 H]thymidine incorporation. In comparison to control B cells, Gfi1 Ϫ/Ϫ B cells showed a higher rate of proliferation in response to anti-CD40, anti-IgM, and LPS (Fig. 4A) , suggesting that Gfi1 restricts B cell hyperproliferation. We performed in vivo BrdU labeling studies to assess whether the proliferative capacity of CD138 ϩ cells is increased in the absence of Gfi1. As expected, the proliferation of CD138 ϩ cells was much higher in Gfi1-deficient mice compared with wild-type littermates (Fig. 4B) , suggesting that the splenic CD138 ϩ cells of Gfi1-deficient mice represent mostly plasma blasts. Further, we investigated whether Gfi1-deficient B cells show enhanced differentiation into CD138 ϩ cells in vitro in response to LPS. Interestingly, both absolute numbers and Ig secretion of in vitro differentiated CD138 ϩ cells were increased in the absence of Gfi1 (Fig. 4, C and D) .
Because Gfi1 may be involved in the transcriptional regulation of multiple genes controlling growth and differentiation, we were interested in analyzing signals emanating from the BCR that are integrated by a cascade of phosphorylation and dephosphorylation events. We analyzed protein lysates of Gfi1-deficient and wildtype B cells for the specific levels of Lyn and Erk phosphorylation, two important elements in the BCR-mediated signal cascade. Although the overall expression levels of both Lyn and Erk were comparable in Gfi1-deficient and wild-type B cells, the phosphorylated forms were increased in Gfi1-deficient B cells (Fig. 4E and  supplemental figure 4) . To measure immediate effects of BCR stimulation, we monitored the release of calcium upon BCR crosslinking. Compared with wild-type B cells, Gfi1-deficient B cells showed a more rapid release of calcium (Fig. 4F and supplemental figure 5 ), suggesting that Gfi1 has a role in integrating the strength of BCR signaling.
Development of autoimmunity in Gfi1-deficient mice is B cell mediated
Because autoimmunity could result from multiple effectors in an abnormal hematopoietic system, we next sought to analyze the role of B cells in the development of autoimmunity. We transferred 10 6 purified CD19 ϩ B cells from Gfi1 Ϫ/Ϫ and Gfi1 ϩ/ϩ mice into NOD/SCID recipient mice. Similarly as Gfi1 Ϫ/Ϫ mice, NOD/ SCID mice injected with Gfi1 Ϫ/Ϫ B cells developed autoantibodies (Fig. 5A) , eczema, ataxia (data not shown), and Ig deposition in the brain, whereas adoptive transfer of control B cells had no effects (Fig. 5B) . Although we cannot rule out that immune effector cells such as dendritic cells (21) and/or T cells (24) may contribute to the autoimmunity in Gfi1-deficient mice, our findings support the notion that unrestricted activation and proliferation of B cells leads to CNS and renal autoimmunity in Gfi1 Ϫ/Ϫ mice.
Identification of downstream target genes of Gfi1 in B cells
Recent evidence has shown that autoreactive B cells can be activated by TLRs, in particular TLR7 and TLR9 (5). We therefore hypothesized that Gfi1 may control transcription of these TLRs or their downstream effectors. However, we could not detect any differences in the mRNA expression levels of TLR7, TLR9, MyD88, and NF-B when comparing Gfi1 Ϫ/Ϫ and Gfi1 ϩ/ϩ B cells (supplemental figure 6 ). To further elucidate the mechanism of Gfi1 in the control of B cell differentiation, we next hypothesized that Gfi1 may control a number of downstream target genes specifying B cell differentiation and cell cycle progression. Using Affymetrix microarray analysis, a comprehensive study of the transcriptome was performed in purified splenic CD19 ϩ
CD138
Ϫ cells from Gfi1 Ϫ/Ϫ and Gfi1 ϩ/ϩ mice, respectively. Six hundred and fortyeight genes were found to be differentially expressed (supplemental table 1). In particular, we identified increased expression of 16 transcription factors and decreased expression of 14 transcription factors in Gfi1 Ϫ/Ϫ B cells (Fig. 6, A and B) . These data indicate a complex dysregulation of transcriptional control in Gfi1 Ϫ/Ϫ B cells. Of interest, expression of Blimp-1 (Prdm1) and XBP-1, two FIGURE 5. B cell-mediated autoimmunity in Gfi1-deficient mice. A, Anti-nuclear Ab titers in NOD/SCID mice injected with 1 ϫ 10 6 purified B220 ϩ CD19 ϩ CD43 Ϫ CD138 Ϫ splenic B cells from either Gfi1 ϩ/ϩ or Gfi1 Ϫ/Ϫ mice. The purity of the sorted cells was Ͼ98%. Animals were sacrificed 8 wk after adoptive transfer and anti-nuclear Ab titers were determined by ELISA. B, Brain sections from NOD/SCID mice 12 wk after adoptive transfer of B220 ϩ CD19 ϩ CD43 Ϫ CD138 Ϫ B cells of spleen from either Gfi1 Ϫ/Ϫ or Gfi1 ϩ/ϩ mice. Sections were stained for IgG Ig. master regulators of plasma cell differentiation, was increased in Gfi1 Ϫ/Ϫ B cells. In view of the hyperproliferative B cell phenotype, we also analyzed the protein expression profile of selected cyclin-dependent kinases. A markedly increased expression of cyclin A2 and B2 as well as decreased expression of the cell cycle inhibitor p21cip1 in Gfi1 Ϫ/Ϫ B cells was seen (Fig. 6C ). These data highlight that multiple pathways are in dysbalance in Gfi1-deficient B cells, yet further studies are needed to document whether these effects are directly or indirectly influenced by Gfi1.
Discussion
We present in this study evidence that Gfi1 deficiency leads to the development of B cell-dependent autoimmunity. Thus, in addition to its complex role in controlling differentiation of hematopoietic cells (19 -26) , Gfi1 is a critical factor in preventing B cell hyperproliferation and production of autoantibodies.
In various murine model systems, B cell hyperproliferation has been linked to autoimmunity (33) . For example, a lack of negative modulators of BCR-mediated signals such as FcgRIIb1 (10), PD-1 (11), or PKC-␦ (12) leads to increased B cell proliferation and autoantibody-mediated lupus-like pathology. Similarly, Shp1 deficiency (13) and increased MyD88 activation due to transgenic BAFF expression (14) causes a strictly B cell-dependent phenotype of lupus-like autoimmunity. In these experimental systems, intrinsic dependency on B cells has been unequivocally documented by using transgenic mice with B cell-specific knockouts or in mice completely deficient in T cells, respectively. Although these studies, along with others, confirm that intrinsic B cell stimulation may result in lupus-like autoimmunity, we cannot rule out that additional factors, such as increased dendritic cell activation (21) or altered T cell development (24, 25) , may contribute to autoimmunity in Gfi1 Ϫ/Ϫ mice (35) . In our view, the possible involvement of non-B lineage cells appears very likely, because the clinical phenotype of Gfi1-deficient mice associating various hematological defects and autoimmunity (in particular in the CNS) is quite unique. Nevertheless, although additional factors may be critical in the initiation of disrupted B cell tolerance, effector functions depend exclusively on B cells because the adoptive transfer of Gfi1 Ϫ/Ϫ CD19 ϩ B cells led to increased autoantibody production in immunodeficient NOD/SCID mice.
The mechanism of increased B cell proliferation is not yet clearly defined and most likely reflects multiple imbalances in various signal transduction pathways. Gfi1-deficient B cells are characterized by increased calcium flux and increased phosphorylation of Lyn and Erk, suggesting that a complex dysregulation of factors controlling proximal events of BCR-mediated signals may contribute to increased B cell proliferation. Interestingly, a reminiscent B cell-mediated immunological phenotype of autoimmunity (increased serum levels of IgG2a, IgA, and anti-nuclear Abs are associated with increased BCR signal strength) has been described in mice transgenic for a point mutation in the CD45 gene (36, 37) . These studies have illuminated that distinct patterns of homodimerization affects the ability of the transmembrane phosphatase CD45 to modulate BCR signaling (36) . CD45 is subject to alternative splicing events that give rise to the expression of distinct isoforms with differential homodimerization potential. Gfi1 has recently been shown to be part of a protein complex controlling the splicing of CD45 (32) . However, the alternative splicing pattern of CD45 in Gfi1 Ϫ/Ϫ B cells cannot easily be reconciled with the finding of a decreased BCR threshold, because in Gfi1 A complex pattern of dysregulated pathways controlling cellular differentiation and cell cycle progression is further supported by our screening studies of the transcriptome in Gfi1-deficient B cells. Multiple transcription factors are differentially expressed in Gfi1-deficient CD19 ϩ CD138 Ϫ peripheral B cells when compared with wild-type cells. Although the transcriptional profile in Gfi1-deficient B cells reflects a program destined to plasma cell differentiation, it remains challenging to directly implicate any of these factors directly in the autoimmune pathology. Blimp-1, a critical factor controlling plasma cell differentiation (15) , has been shown to repress proliferation (38) and thus is unlikely to account for this effect. In contrast, Tbx21 (T-bet) has recently been implicated in B cell development and appears to maintain a type 1-like differentiation program in B cells in response to IFN-␥ and CpG oligonucleotides (39, 40) . In Gfi1 Ϫ/Ϫ B cells, an increase in T-bet may favor the generation of pathogenic autoantibodies via the induction of IgG2a class switching and affinity maturation (41) . A limitation of the transcriptional profiling approach may be a potential bias in earlier steps of B cell differentiation in the absence of Gfi1 (26) . Nevertheless, the transcriptional profile reflects a complex dysregulation of Gfi1-dependent events and may allow the identification of potential novel molecular targets of Gfi1. These studies are further supported by our experiments determining the protein level of critical cell cycle regulators. Our findings are reminiscent of the altered expression of cell cycle regulators in Gfi1-deficient hematopoietic stem cells (22, 23) and may also account for increased proliferative activity of Gfi1-deficient B cells. Further studies are necessary to understand the complex regulatory role of Gfi1 in restricting B cell-dependent autoimmunity.
In summary, we provide evidence that Gfi1-deficient mice develop an autoimmune phenotype that might at least partially be due to aberrant signaling in B lineage cells. These studies provide an example of how a single factor controls B cell-mediated autoimmunity and should be helpful in future attempts aimed at the molecular dissection of human autoimmune diseases.
